jorveza
dr. falk pharma gmbh - budesonide - ochorenia pažeráka - antidiarrheals, črevné protizápalové / antiinfective agentov - jorveza je indikovaná na liečbu eozinofilnej ezofagitídy (eoe) u dospelých (starších ako 18 rokov).
copalia
novartis europharm limited - valsartan, amlodipine (as amlodipine besilate) - vysoký tlak - Činidlá pôsobiace na systém renín-angiotenzín - liečba esenciálnej hypertenzie. copalia je indikovaný u pacientov, ktorých krvný tlak nie je primerane kontrolované na amlodipine alebo valsartan monotherapy.
tevafos 20 mg/12,5 mg tablety
teva b.v. - fozinopril a diuretiká - 58 - hypotensiva
velphoro
vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - lieky na liečbu hyperkalemia a hyperphosphatemia - velphoro je indikovaná na kontrolu hladiny fosforu v sére dospelých chronickou obličkovou chorobou (ckd) pacientov na hemodialýze (hd) alebo peritoneálnej dialýze (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - imunosupresíva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
veltassa
vifor fresenius medical care renal pharma france - patiromer sorbitex vápnik - hyperkaliémia - lieky na liečbu hyperkalemia a hyperphosphatemia - veltasa je indikovaná na liečbu hyperkaliémie u dospelých.
sitagliptin sun
sun pharmaceutical industries europe b.v. - sitagliptin fumarate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus, sitagliptin sun is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. a thiazolidinedione) when use of a pparγ agonist is appropriate and when diet and exercise plus the pparγ agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a pparγ agonist and metformin when use of a pparγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin sun is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.
vivotif
bavarian nordic a/s, dánsko - očkovacia látka proti týfusu, perorálna, živá oslabená - 59 - immunopraeparata